A Phase 2 interventional study of Nivolumab + Paclitaxel and Cetuximab + Paclitaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello. Completed at 21 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-26.
Sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello · Phase 2, Interventional, and Treatment
How we know · 8 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 15 under way, 2 of them phase 3. Nivolumab · Squamous Cell Carcinoma of Head and Neck.
Among the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, this one is the 9th largest by enrollment, is one of 4 that started in 2020, is one of 27 in phase 2, and was the 28th registered.
2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →11 of the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck are open now, in 7 countries. Recruiting first, the newest first:
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+
National University Hospital, Singapore · Sites in Singapore
Ages 21–99
Mayo Clinic · Sites in United States
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 32 · Phase 3 7
First in 2014; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 141 is above the median of 48 across 1,657 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 44 across the 46 interventional studies. Of the 27 that completed or were terminated, 18 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 46 have an industry lead sponsor. The 10 most frequent:
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello has 4 studies filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
5 of the studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03576417Phase 3Groupe Oncologie Radiotherapie Tete et CouA Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck | 2027-08 |
| NCT05136196National Cancer Institute (NCI)BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | 2027-01-01 |
| NCT06265285Mayo ClinicComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | 2027-05-01 |
| NCT04831320Washington University School of MedicineNab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor | 2027-06-30 |
| NCT03406247Gustave Roussy, Cancer Campus, Grand ParisAdjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma is palliative and usually platinum based, and the patients often present with poor physical condition. Consequently, many of them are not able to withstand a platinum-based chemotherapy. The addition of taxanes to the armamentarium of drugs improve the outcome in this group of patients. An alternative and better tolerated regimen for these patients is paclitaxel in combination with cetuximab, included the in guidelines of the Spanish Society of Medical Oncology.
Recently, new treatments such as immune-checkpoint inhibitors have shown promising activity and good tolerability in patients with recurrent or metastatic head and neck squamous cell carcinoma and has been included in the recently published guidelines from the Society for Immunotherapy of Cancer. Nivolumab (anti-PD1) has been approved for patients progressing on or after platinum-based therapy, as it clearly impacts on overall survival.
This randomized phase II study will evaluate the efficacy of nivolumab plus paclitaxel for first-line treatment of recurrent or metastatic HNSCC in the platinum ineligible and platinum refractory settings. Control arm will be paclitaxel in combination with cetuximab, treatment included in the guidelines of the Spanish Society of Medical Oncology.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients unable for cisplatin-based chemotherapy, defined "unable" by:
i. Impaired renal function, >30 mL/min and \<80 mL/min could be assessed by direct measurement (EDTA or creatinine clearance) if available or by calculation from serum or plasma creatinine (see annex 5), or
ii. grade ≥2 hearing loss, according to the v 5.0, or
iii. Class III heart failure according to the (annex 9), or
iv. History of allergic reactions to cisplatin, carboplatin, or other platinum-containing compounds or
v. Prior dose of cisplatin ≥225 mg/m² for locally advanced disease (a patient who received prior RT + 3 cycles of cisplatin 100 mg/m2 or 3 cycles induction TPF (with cisplatin ≥75/m2) for locally advanced primary HN cancer can be included), or
vi. Disease progression or relapse during or within 6 months of receiving platinum-based therapy administered as , adjuvant therapy or as concomitant chemotherapy with radiotherapy and have received at least 200 mg/m2 of cisplatin.
Clinical laboratory values as specified below within 28 days before the first dose of study drug:
Exclusion Criteria:
Patients that meets more than one of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NIVOTAX (nivolumab + paclitaxel, follow by maintenance with nivolumab)
Drug: Nivolumab + Paclitaxel
ERBITAX (cetuximab + paclitaxel, follow by maintenance with cetuximab)
Drug: Cetuximab + Paclitaxel
Drug pages: NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Combination treatment: Nivolumab 240 mg will be administered via IV infusion every 2 weeks. Paclitaxel 80mg/m2 will be administered via IV infusion weekly. After 12 weeks from the start of the combined treatment paclitaxel will be stopped. Maintenance treatment with nivolumab 480 mg every 4 weeks will start two weeks after the last administration of nivolumab 240 mg. Once nivolumab is administered at 480 mg, paclitaxel can no longer be administered. Nivolumab will be continued alone until disease progression, unacceptable toxicity or withdrawal of consent up to a maximum of 24 months.
Drug pages: CetuximabStudies of CetuximabCetuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Combination treatment: Cetuximab 250 mg/m2 (first dose of 400 mg/m2) administered via IV infusion weekly plus weekly paclitaxel (80 mg/m2) administered via IV infusion. After 12 weeks from the start of the combined treatment paclitaxel will be stopped and weekly cetuximab will be continued alone until disease progression, unacceptable toxicity or withdrawal of consent up to a maximum of 24 months.
Two Years Overall Survival (OS)
OS is defined as the time between the date of randomization and the date of death. For subjects without documentation of death, OS will be censored on the last date the subject was known to be alive.
Time frame: 2 years
Progression Free Survival (PFS)
PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.
Time frame: Up to 45 months
Overall Response Rate (ORR)
ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.
Time frame: Up to 2 years
Disease Control Rate (DCR)
Disease control rate (DCR) is defined as the number of subjects with a best overall response (BOR) of a complete response (CR), partial response (PR) or stable disease (SD) divided by the number of randomized subjects for each treatment group.
Time frame: Up to 2 years
Duration of Response (DoR)
Duration of Response (DoR) is defined as the time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first.
Time frame: Up to 45 months
6-months Progression-free Survival Rate
Probability of progression at 6 months.
Time frame: 6 months
Overall Survival in Patients ≥ 70 Years.
OS is defined as the time between the date of randomization and the date of death.
Time frame: Up to 45 months
Progression Free Survival in Patients ≥ 70 Years.
PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.
Time frame: Up to 45 months
Overall Response Rate in Patients ≥ 70 Years.
ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.
Time frame: Up to 2 years
Overall Survival Based on PDL1 Expression (CPS).
OS is defined as the time between the date of randomization and the date of death.
Time frame: Up to 45 months
Progression Free Survival Based on PDL1 Expression (CPS).
PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.
Time frame: Up to 45 months
Overall Response Rate Based on PDL1 Expression (CPS).
ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.
Time frame: Up to 2 years
Overall Survival Based on Cisplatin Ineligibility.
OS is defined as the time between the date of randomization and the date of death.
Time frame: Up to 45 months
Progression Free Survival Based on Cisplatin Ineligibility.
PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.
Time frame: Up to 45 months
Overall Response Rate Based on Cisplatin Ineligibility.
ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.
Time frame: Up to 2 years
Overall Survival Based on Karnofsky.
OS is defined as the time between the date of randomization and the date of death.
Time frame: Up to 45 months
Progression Free Survival Based on Karnofsky.
PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.
Time frame: Up to 45 months
Overall Response Rate Based on Karnofsky.
ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.
Time frame: Up to 2 years
Percentage of Patients With AEs
Percentage of patients with AEs in relation with total number of treated patients
Time frame: 2 years
Percentage of Patients With Grade 3 and Grade 4 AEs
Percentage of patients with Grade 3 and Grade 4 AEs in relation with total number of treated patients
Time frame: 2 years
Percentage of Patients With SAEs
Percentage of patients with SAEs in relation with total number of treated patients
Time frame: Up to 45 months
Percentage of Patients Who Discontinued Due to AEs
Percentage of patients who discontinued due to AEs in relation with total number of treated patients
Time frame: Up to 2 years
| Milestone | Arm 1 | Arm 2 |
|---|---|---|
| Started | 93 | 48 |
| Completed | 93 | 48 |
| Not completed | 0 | 0 |
OS is defined as the time between the date of randomization and the date of death. For subjects without documentation of death, OS will be censored on the last date the subject was known to be alive.
| percentage of participants | Arm 1 | Arm 2 |
|---|---|---|
| Two Years Overall Survival (OS) | 24.7 (15.9 to 33.5) | 13.4 (3.6 to 23.2) |
PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.
| months | Arm 1 | Arm 2 |
|---|---|---|
| Progression Free Survival (PFS) | 5.6 (3.5 to 7.6) | 5.3 (2.7 to 7.9) |
ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.
| percentage of participants | Arm 1 | Arm 2 |
|---|---|---|
| Overall Response Rate (ORR) | 37.6 (27.8 to 47.5) | 37.5 (23.8 to 51.2) |
Disease control rate (DCR) is defined as the number of subjects with a best overall response (BOR) of a complete response (CR), partial response (PR) or stable disease (SD) divided by the number of randomized subjects for each treatment group.
| percentage of participants | Arm 1 | Arm 2 |
|---|---|---|
| Disease Control Rate (DCR) | 74.2 (65.3 to 83.1) | 79.2 (67.7 to 90.7) |
Duration of Response (DoR) is defined as the time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first.
| month | Arm 1 | Arm 2 |
|---|---|---|
| Duration of Response (DoR) | 9 (7.6 to 10.5) | 7.6 (4.9 to 10.4) |
Probability of progression at 6 months.
| percentage of participants | Arm 1 | Arm 2 |
|---|---|---|
| 6-months Progression-free Survival Rate | 47.5 (37.3 to 57.7) | 50.0 (35.9 to 64.1) |
OS is defined as the time between the date of randomization and the date of death.
| months | Arm 1 | Arm 2 |
|---|---|---|
| Overall Survival in Patients ≥ 70 Years. | 13.03 (3.9 to 22.2) | 14.54 (7.99 to 21.01) |
PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.
| month | Arm 1 | Arm 2 |
|---|---|---|
| Progression Free Survival in Patients ≥ 70 Years. | 6.48 (2.22 to 10.73) | 9.97 (3.59 to 16.34) |
ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.
| percentage of participants | Arm 1 | Arm 2 |
|---|---|---|
| Overall Response Rate in Patients ≥ 70 Years. | 40.5 | 53.8 |
OS is defined as the time between the date of randomization and the date of death.
| months | Arm 1 - CPS <1 | Arm 1 - CPS >=1 | Arm 2 - CPS <1 | Arm 2 - CPS >=1 |
|---|---|---|---|---|
| Overall Survival Based on PDL1 Expression (CPS). | 11.94 (8.55 to 15.33) | 12.24 (8.90 to 15.57) | 14.54 (7.51 to 21.57) | 11.18 (8.99 to 13.38) |
PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.
| months | Arm 1 - CPS <1 | Arm 1 - CPS >=1 | Arm 2 - CPS <1 | Arm 2 - CPS >=1 |
|---|---|---|---|---|
| Progression Free Survival Based on PDL1 Expression (CPS). | 7.6 (0.55 to 14.65) | 5.56 (4.16 to 6.95) | 8.72 (2.65 to 14.79) | 5.33 (2.94 to 7.71) |
ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.
| percentage of participants | Arm 1 - CPS <1 | Arm 1 - CPS >=1 | Arm 2 - CPS <1 | Arm 2 - CPS >=1 |
|---|---|---|---|---|
| Overall Response Rate Based on PDL1 Expression (CPS). | 45.0 | 35.6 | 27.3 | 40.5 |
OS is defined as the time between the date of randomization and the date of death.
| months | Arm 1 - Group 1 | Arm 1 - Group 2 | Arm 1 - Group 3 | Arm 2 - Group 1 | Arm 2 - Group 2 | Arm 2 - Group 3 |
|---|---|---|---|---|---|---|
| Overall Survival Based on Cisplatin Ineligibility. | 8.95 (2.08 to 15.82) | 14.14 (11.39 to 16.90) | 10.49 (6.55 to 14.44) | 7.5 (4.83 to 10.16) | 14.54 (8.85 to 20.23) | 12.14 (7.7 to 16.61) |
PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.
| months | Arm 1 - Group 1 | Arm 1 - Group 2 | Arm 1 - Group 3 | Arm 2 - Group 1 | Arm 2 - Group 2 | Arm 2 - Group 3 |
|---|---|---|---|---|---|---|
| Progression Free Survival Based on Cisplatin Ineligibility. | 4.84 (0.11 to 9.56) | 5.56 (3.02 to 8.1) | 10.23 (6.63 to 16.83) | 2.53 (1.78 to 3.24) | 7.53 (6.64 to 8.43) | 8.26 (6.8 to 9.71) |
ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.
| percentage of participants | Arm 1 - Group 1 | Arm 1 - Group 2 | Arm 1 - Group 3 | Arm 2 - Group 1 | Arm 2 - Group 2 | Arm 2 - Group 3 |
|---|---|---|---|---|---|---|
| Overall Response Rate Based on Cisplatin Ineligibility. | 32.0 | 39.6 | 40.0 | 15.4 | 51.9 | 25.0 |
OS is defined as the time between the date of randomization and the date of death.
| months | Arm 1 - Karnofsky-PS 70% | Arm 1 - Karnofsky-PS 80-100% | Arm 2 - Karnofsky-PS 70% | Arm 2 - Karnofsky-PS 80-100% |
|---|---|---|---|---|
| Overall Survival Based on Karnofsky. | 13.03 (10.04 to 16.01) | 11.32 (6.45 to 16.19) | 11.18 (6.48 to 15.89) | 12.14 (10.68 to 13.59) |
PFS is defined as the time from randomization to the date of first documented disease progression, as assessed by the investigator using RECIST 1.1 criteria, or death due to any cause, whichever occurs first.
| months | Arm 1 - Karnofsky-PS 70% | Arm 1 - Karnofsky-PS 80-100% | Arm 2 - Karnofsky-PS 70% | Arm 2 - Karnofsky-PS 80-100% |
|---|---|---|---|---|
| Progression Free Survival Based on Karnofsky. | 6.48 (3.39 to 9.56) | 5.56 (4.2 to 6.92) | 4.84 (3.80 to 5.87) | 7.07 (3.38 to 10.76) |
ORR is defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects for each treatment group.
| percentage of participants | Arm 1 - Karnofsky-PS 70% | Arm 1 - Karnofsky-PS 80-100% | Arm 2 - Karnofsky-PS 70% | Arm 2 - Karnofsky-PS 80-100% |
|---|---|---|---|---|
| Overall Response Rate Based on Karnofsky. | 41.6 | 35.1 | 43.7 | 34.4 |
Percentage of patients with AEs in relation with total number of treated patients
| percentage of participants | Arm 1 | Arm 2 |
|---|---|---|
| Percentage of Patients With AEs | 100 | 100 |
Percentage of patients with Grade 3 and Grade 4 AEs in relation with total number of treated patients
| percentage of participants | Arm 1 | Arm 2 |
|---|---|---|
| Percentage of Patients With Grade 3 and Grade 4 AEs | 72.0 | 68.8 |
Percentage of patients with SAEs in relation with total number of treated patients
| percentage of participants | Arm 1 | Arm 2 |
|---|---|---|
| Percentage of Patients With SAEs | 57.0 | 54.2 |
Percentage of patients who discontinued due to AEs in relation with total number of treated patients
| percentage of participants | Arm 1 - Combination Phase | Arm 1 - Monotherapy Phase | Arm 2 - Combination Phase | Arm 2 - Monotherapy Phase |
|---|---|---|---|---|
| Percentage of Patients Who Discontinued Due to AEs | 14.0 | 10.2 | 10.4 | 6.1 |
Collected over Up to 45 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 | 79/93 (84.9%) | 53/93 (57%) | 93/93 (100%) |
| Arm 2 | 43/48 (89.6%) | 26/48 (54.2%) | 48/48 (100%) |
| Event | Arm 1 | Arm 2 |
|---|---|---|
| Respiratory tract infectionInfections and infestations | 6/93 | 6/48 |
| PneumoniaInfections and infestations | 9/93 | 2/48 |
| DysphagiaGastrointestinal disorders | 7/93 | 1/48 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 6/93 | 1/48 |
| VomitingGastrointestinal disorders | 0/93 | 2/48 |
| Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/93 | 1/48 |
| SepsisInfections and infestations | 3/93 | 1/48 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/93 | 1/48 |
| Product dispensing errorInjury, poisoning and procedural complications | 2/93 | 0/48 |
| Immune-mediated hepatitisHepatobiliary disorders | 2/93 | 0/48 |
| Event | Arm 1 | Arm 2 |
|---|---|---|
| AstheniaGeneral disorders | 57/93 | 29/48 |
| RashSkin and subcutaneous tissue disorders | 10/93 | 25/48 |
| AnaemiaBlood and lymphatic system disorders | 41/93 | 19/48 |
| Mucosal inflammationGeneral disorders | 15/93 | 16/48 |
| HypomagnesaemiaMetabolism and nutrition disorders | 6/93 | 15/48 |
| ConstipationGastrointestinal disorders | 23/93 | 14/48 |
| DiarrhoeaGastrointestinal disorders | 26/93 | 14/48 |
| Decreased appetiteMetabolism and nutrition disorders | 17/93 | 14/48 |
| AlopeciaSkin and subcutaneous tissue disorders | 26/93 | 6/48 |
| NeurotoxicityNervous system disorders | 22/93 | 10/48 |
| Age, Categorical(Participants) | Arm 1 | Arm 2 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 42 | 27 | 69 |
| >=65 years | 51 | 21 | 72 |
| Age, Continuous(years) | Arm 1 | Arm 2 | Total |
|---|---|---|---|
| Mean | 66.8 (59 to 75) | 64 (57 to 70.5) | 65.9 (58 to 74) |
| Sex: Female, Male(Participants) | Arm 1 | Arm 2 | Total |
|---|---|---|---|
| Female | 20 | 12 | 32 |
| Male | 73 | 36 | 109 |
| Race/Ethnicity, Customized(Participants) | Arm 1 | Arm 2 | Total |
|---|---|---|---|
| White/Caucasian | 93 | 47 | 140 |
| Arab | 0 | 1 | 1 |
| Smoking habits: Has the patient ever smoked?(Participants) | Arm 1 | Arm 2 | Total |
|---|---|---|---|
| Yes | 75 | 11 | 86 |
| No | 18 | 37 | 55 |
| Metastatic disease at diagnosis(Participants) | Arm 1 | Arm 2 | Total |
|---|---|---|---|
| Yes | 8 | 3 | 11 |
| No | 85 | 45 | 130 |
| Karnofsky performance status(Participants) | Arm 1 | Arm 2 | Total |
|---|---|---|---|
| 70% | 36 | 16 | 52 |
| 80-100% | 57 | 32 | 89 |
| PD-L1 CPS(Participants) | Arm 1 | Arm 2 | Total |
|---|---|---|---|
| <1 | 20 | 11 | 31 |
| ≥1 | 73 | 37 | 110 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2020 to primary completion in Sep 2023, 38 months.
Results were first posted in Jun 2025, 1 year 9 months after primary completion.
Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's 38 months is below that.
Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Paclitaxel
Squamous Cell Carcinoma of Head and Neck →
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello